Iovance Biotherapeutics Stock Alpha and Beta Analysis
| IOVA Stock | USD 6.07 0.12 1.94% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Iovance Biotherapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Iovance Biotherapeutics over a specified time horizon. Remember, high Iovance Biotherapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Iovance Biotherapeutics' market risk premium analysis include:
Beta 1.14 | Alpha (0.75) | Risk 4.09 | Sharpe Ratio (0.24) | Expected Return (0.98) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Iovance |
Iovance Biotherapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Iovance Biotherapeutics market risk premium is the additional return an investor will receive from holding Iovance Biotherapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Iovance Biotherapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Iovance Biotherapeutics' performance over market.| α | -0.75 | β | 1.14 |
Iovance Biotherapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Iovance Biotherapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Iovance Biotherapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Iovance Biotherapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Iovance Biotherapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Iovance Biotherapeutics shares will generate the highest return on investment. By understating and applying Iovance Biotherapeutics stock market price indicators, traders can identify Iovance Biotherapeutics position entry and exit signals to maximize returns.
Iovance Biotherapeutics Return and Market Media
The median price of Iovance Biotherapeutics for the period between Sat, Nov 2, 2024 and Fri, Jan 31, 2025 is 8.19 with a coefficient of variation of 20.82. The daily time series for the period is distributed with a sample standard deviation of 1.74, arithmetic mean of 8.37, and mean deviation of 1.41. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 10417 shares by Vogt Frederick G of Iovance Biotherapeutics subject to Rule 16b-3 | 11/07/2024 |
2 | Disposition of 50000 shares by Maynard Ryan D of Iovance Biotherapeutics at 7.45 subject to Rule 16b-3 | 11/12/2024 |
3 | Is Iovance Biotherapeutics Stock a Millionaire Maker | 11/27/2024 |
4 | Disposition of 06 shares by Graf Finckenstein Friedrich of Iovance Biotherapeutics subject to Rule 16b-3 | 12/02/2024 |
5 | Disposition of 8334 shares by Puri Raj K. of Iovance Biotherapeutics subject to Rule 16b-3 | 12/16/2024 |
6 | If I Could Only Buy 3 Stocks in the Last Month of 2024, Id Pick These | 12/19/2024 |
7 | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 | 12/20/2024 |
8 | Iovance Biotherapeutics Shares Up 7.7 percent Heres What Happened | 01/02/2025 |
9 | Why Iovance Biotherapeutics Stock Zoomed More Than 5 percent Higher Today | 01/03/2025 |
10 | Disposition of 2813 shares by Igor Bilinsky of Iovance Biotherapeutics subject to Rule 16b-3 | 01/14/2025 |
11 | Iovance Biotherapeutics Inc Announces Inducement Stock Options for New Employees | 01/17/2025 |
12 | Iovance Biotherapeutics Sets New 52-Week Low Heres Why | 01/21/2025 |
13 | Acquisition by Vogt Frederick G of 20835 shares of Iovance Biotherapeutics subject to Rule 16b-3 | 01/24/2025 |
14 | Acquisition by Vogt Frederick G of 10417 shares of Iovance Biotherapeutics subject to Rule 16b-3 | 01/27/2025 |
About Iovance Biotherapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Iovance or other stocks. Alpha measures the amount that position in Iovance Biotherapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2024 | 2025 (projected) | Dividend Yield | 0.13 | 0.12 | 0.1 | Price To Sales Ratio | 1.6K | 1.4K | 1.3K |
Iovance Biotherapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Iovance Biotherapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Iovance Biotherapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Iovance Biotherapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Iovance Biotherapeutics. Please utilize our Beneish M Score to check the likelihood of Iovance Biotherapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Iovance Biotherapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Iovance Biotherapeutics Backtesting, Iovance Biotherapeutics Valuation, Iovance Biotherapeutics Correlation, Iovance Biotherapeutics Hype Analysis, Iovance Biotherapeutics Volatility, Iovance Biotherapeutics History and analyze Iovance Biotherapeutics Performance. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Iovance Biotherapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.